RCT | Ecopipam for Tourette Syndrome
15 Jan, 2023 | 20:09h | UTCEcopipam for Tourette Syndrome: A Randomized Trial – Pediatrics
Commentary: Ecopipam May Reduce Tics in Children With Tourette Syndrome – Psychiatric News Alert
Commentary on Twitter
Ecopipam, a selective D1-like receptor antagonist, is in development for children & adolescents with Tourette syndrome. Can ecopipam achieve a clinically meaningful reduction in tics without the disadvantages of D2-like receptor antagonists? https://t.co/GXxnPsP74C #Pediatrics pic.twitter.com/14fwu4npJi
— AAP Pediatrics (@aap_peds) January 11, 2023